person · Reporting owner

Berkman Charles S

Disclosed activity across 3 companies

Tapewire entity: 53378
SEC CIK: 0001392266

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
OmniAb, Inc.OABI · Entity 5294	Chief Legal Officer	April 07, 2026	April 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OmniAb, Inc.

Report date April 07, 2026 · Filed April 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	399,085	Ending reported balance After 2026-04-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-04-07 · Exercise / conversion · Acquired 13,542 · Balance 406,242 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 7,157 · Balance 399,085 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	111,042	Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-07 · Exercise / conversion · Disposed 13,542 · Balance 111,042 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LIGAND PHARMACEUTICALS INC

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,825	Reported balance After 2022-11-01 transaction · row 1 1 source row Row 1 · 2022-11-01 · Disposition to issuer · Disposed 11,944 · Balance 23,825 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 20,126 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.

F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

OmniAb Operations, Inc.

Report date November 01, 2022 · Filed November 04, 2022

Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	52,587	Reported balance After 2022-11-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-11-01 · Grant · Acquired 15,409 · Balance 52,587 F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-11-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2022-11-01 · Disposition to issuer · Disposed 52,587 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	35,810	Reported balance After 2022-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-11-01 · Grant · Acquired 35,810 · Balance 35,810 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05	Direct	0	Reported balance After 2022-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-11-01 · Disposition to issuer · Disposed 35,810 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10	Direct	0	Reported balance After 2022-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-11-01 · Disposition to issuer · Disposed 1,701 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-11-01 · Disposition to issuer · Disposed 3,627 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24	Direct	0	Reported balance After 2022-11-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-11-01 · Disposition to issuer · Disposed 5,966 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02	Direct	0	Reported balance After 2022-11-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-11-01 · Disposition to issuer · Disposed 8,117 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11	Direct	0	Reported balance After 2022-11-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-11-01 · Disposition to issuer · Disposed 12,797 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13	Direct	0	Reported balance After 2022-11-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-11-01 · Disposition to issuer · Disposed 15,043 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03	Direct	0	Reported balance After 2022-11-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-11-01 · Disposition to issuer · Disposed 6,076 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.

F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.

F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.

F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.

F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.

F6: The stock option is fully vested and exercisable.

F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.

F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.

F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 15, 2023 Filed Feb 18, 2023 00:50 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	2,166	$3.80	$8,230.80	Disclosure SEC source: 0001846253-23-000016 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,939 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document
February 15, 2023 Filed Feb 18, 2023 00:50 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	5,404	$3.80	$20,535.20	Disclosure SEC source: 0001846253-23-000016 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,105 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document
February 15, 2023 Filed Feb 18, 2023 00:50 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	1,973	$3.80	$7,497.40	Disclosure SEC source: 0001846253-23-000016 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,509 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document
January 03, 2023 Filed Jan 5, 2023 22:06 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	46,864	$0.00	$0.00	Disclosure SEC source: 0000899243-23-001020 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,482 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments beginning on December 7, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
December 28, 2022 Filed Dec 30, 2022 22:00 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	6,518	$3.66	$23,855.88	Disclosure SEC source: 0000899243-22-039582 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,618 Read SEC document
December 07, 2022 Filed Dec 9, 2022 23:00 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	175,477	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0000899243-22-038122 · doc4.xml · derivative · entry 1 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,477 Underlying: Common Stock · 175,477 shares Expires 2032-12-07 F1 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on June 7, 2023, and in 42 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
December 01, 2022 Filed Dec 6, 2022 02:41 UTC	OmniAb, Inc. OABI · Entity 5294	Tax withholdingCommon Stock	10,580	$3.35	$35,443.00	Disclosure SEC source: 0000899243-22-037744 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,136 Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:06 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	20,126	Not disclosed Strike: $90.68	Not disclosed	Disclosure SEC source: 0000899243-22-035038 · doc4.xml · derivative · entry 2 Berkman Charles S · CIK 0001392266 · Former Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,126 shares Expires 2032-05-05 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:06 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Disposition to issuerCommon Stock	11,944	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035038 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · Former Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,825 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	175,477	Not disclosed Strike: $10.41	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 9 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,477 Underlying: Common Stock · 175,477 shares Expires 2032-05-05 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	29,772	Not disclosed Strike: $20.36	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 8 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,772 Underlying: Common Stock · 29,772 shares Expires 2031-02-03 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F7 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	73,716	Not disclosed Strike: $10.98	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 7 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,716 Underlying: Common Stock · 73,716 shares Expires 2030-02-13 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F6 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	62,710	Not disclosed Strike: $13.54	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 6 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,710 Underlying: Common Stock · 62,710 shares Expires 2029-02-11 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	39,777	Not disclosed Strike: $18.24	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 5 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,777 Underlying: Common Stock · 39,777 shares Expires 2028-03-02 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	29,237	Not disclosed Strike: $11.52	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,237 Underlying: Common Stock · 29,237 shares Expires 2027-02-24 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	17,778	Not disclosed Strike: $9.84	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,778 Underlying: Common Stock · 17,778 shares Expires 2026-02-11 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantStock Option · Derivative	8,339	Not disclosed Strike: $6.46	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · derivative · entry 2 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,339 Underlying: Common Stock · 8,339 shares Expires 2025-02-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:16 UTC	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	353,716	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035063 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,716 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: Includes 97,769 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F3 · shares: Includes 96,038 earn-out shares subject to forfeiture provisions described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	6,076	Not disclosed Strike: $99.75	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 11 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,076 shares Expires 2031-02-03 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F9 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	15,043	Not disclosed Strike: $53.77	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 10 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,043 shares Expires 2030-02-13 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	12,797	Not disclosed Strike: $66.30	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 9 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,797 shares Expires 2029-02-11 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F7 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	8,117	Not disclosed Strike: $89.36	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 8 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,117 shares Expires 2028-03-02 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	5,966	Not disclosed Strike: $56.41	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 7 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,966 shares Expires 2027-02-24 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	3,627	Not disclosed Strike: $48.21	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 6 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,627 shares Expires 2026-02-11 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	1,701	Not disclosed Strike: $31.62	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 5 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,701 shares Expires 2025-02-10 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerStock Option · Derivative	35,810	Not disclosed Strike: $50.96	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,810 shares Expires 2032-05-05 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	GrantStock Option · Derivative	35,810	$0.00 Strike: $50.96	$0.00	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,810 Underlying: Common Stock · 35,810 shares Expires 2032-05-05 F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	Disposition to issuerCommon Stock	52,587	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:08 UTC	OmniAb Operations, Inc. NONE · Entity 122629	GrantCommon Stock	15,409	$0.00	$0.00	Disclosure SEC source: 0000899243-22-035045 · doc4.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,587 F1 · shares: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2 · balance_after: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3 · balance_after: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. Read SEC document
November 01, 2022 Filed Apr 23, 2024 21:42 UTC Amendment	OmniAb, Inc. OABI · Entity 5294	GrantCommon Stock	366,511	Not disclosed	Not disclosed	Disclosure SEC source: 0001846253-24-000012 · wk-form4a_1713908521.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,412 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: This amendment is being filed to correct a Form 4 filed on November 3, 2022, which inadvertently understated the number of shares beneficially held by the Reporting Person following the transaction reported by 12,795 shares. The number reported in column 4 represents the correct number of shares acquired by the Reporting Person as of November 1, 2022, which included (1) 97,769 restricted stock units and (2) 115,346 earn-out shares. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F3 · balance_after: Represents the number of shares beneficially held by the Reporting Person as of the date of this filing, as adjusted for the administrative error identified in footnote 2. Read SEC document
June 10, 2022 Filed Jun 14, 2022 21:55 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	5,375	$0.00	$0.00	Disclosure SEC source: 0000886163-22-000093 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,769 Read SEC document
May 05, 2022 Filed May 10, 2022 00:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	20,126	$0.00 Strike: $90.68	$0.00	Disclosure SEC source: 0000886163-22-000057 · edgardoc.xml · derivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,126 Underlying: Common Stock · 20,126 shares Expires 2032-05-05 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 3-year, 9-month period measured from the date of grant, 12-1/2% after three months, then 1/48th of the Option Shares per month thereafter. The date of grant is 05/05/2022. Read SEC document
February 15, 2022 Filed Feb 17, 2022 01:24 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	577	$123.68	$71,363.36	Disclosure SEC source: 0000886163-22-000024 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,394 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021. Read SEC document
February 15, 2022 Filed Feb 17, 2022 01:24 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	633	$123.68	$78,289.44	Disclosure SEC source: 0000886163-22-000024 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document
February 15, 2022 Filed Feb 17, 2022 01:24 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	368	$123.68	$45,514.24	Disclosure SEC source: 0000886163-22-000024 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:42 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	1,326	$113.68	$150,739.68	Disclosure SEC source: 0000886163-22-000012 · edgardoc.xml · nonDerivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,972 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:42 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	830	$113.68	$94,354.40	Disclosure SEC source: 0000886163-22-000012 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,298 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:42 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	3,836	$0.00	$0.00	Disclosure SEC source: 0000886163-22-000012 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,128 F2 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/09/2020 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:42 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	2,401	$0.00	$0.00	Disclosure SEC source: 0000886163-22-000012 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,292 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
February 15, 2021 Filed Feb 18, 2021 23:28 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	442	$172.46	$76,227.32	Disclosure SEC source: 0000886163-21-000043 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,891 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document
February 15, 2021 Filed Feb 18, 2021 23:28 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	368	$172.46	$63,465.28	Disclosure SEC source: 0000886163-21-000043 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,333 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document
February 15, 2021 Filed Feb 18, 2021 23:28 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	205	$172.46	$35,354.30	Disclosure SEC source: 0000886163-21-000043 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,701 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document
February 04, 2021 Filed Feb 5, 2021 22:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	SaleCommon Stock	18,097	$178.50	$3,230,376.03	Disclosure SEC source: 0000886163-21-000030 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,906 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.33 to $179.90, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 03, 2021 Filed Feb 5, 2021 22:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	6,955	$0.00 Strike: $177.50	$0.00	Disclosure SEC source: 0000886163-21-000030 · edgardoc.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,955 Underlying: Common Stock · 6,955 shares Expires 2021-02-03 F2 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021. Read SEC document
February 03, 2021 Filed Feb 5, 2021 22:03 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	3,491	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000030 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,003 Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:02 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	830	$156.01	$129,488.30	Disclosure SEC source: 0000886163-21-000013 · edgardoc.xml · nonDerivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,512 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:02 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	2,401	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000013 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,342 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:02 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	509	$156.10	$79,454.90	Disclosure SEC source: 0000886163-21-000013 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,941 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:02 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	1,335	$0.00	$0.00	Disclosure SEC source: 0000886163-21-000013 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,450 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document
June 30, 2020 Filed Jul 2, 2020 00:06 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	OtherCommon Stock	238	$89.03	$21,188.90	Disclosure SEC source: 0000886163-20-000084 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,115 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.